Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00940901 · ClinicalTrials.gov registry record · Phase 2

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

A Phase 2 study of Sickle Cell Disease and Priapism, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 2
Development phase
13
Enrollment target
1
Study location

NCT00940901: Completed Phase 2 study of Sickle Cell Disease and Priapism, sponsored by Johns Hopkins University.

NCT00940901 is a Phase 2 study of Sickle Cell Disease and Priapism that has completed, run by Johns Hopkins University. The registered enrollment target is 13 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00940901, a Phase 2 study of Sickle Cell Disease and Priapism, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 2
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

This research is being done to evaluate if the phosphodiesterase type 5 (PDE5) inhibitor sildenafil has an effect on the frequency of recurrent priapism and the quality of life of males with sickle cell disease (SCD).

Primary Outcome

A "Priapism sexual activity log" was administered to participants. In the log, participants were asked to quantify the number of priapic episodes they had experienced in the previous 2 weeks according to the following scale/tiers: 0 = no episodes, 1 = 1-2 episodes, 2 = 3-4 episodes, 3 = 5-8 episodes and 6 = greater than 20 episodes.

Conditions Studied

Sickle Cell Disease Priapism

Interventions

  • OTHER placebo
  • DRUG sildenafil

Study Locations (1)

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2008-06
Est. Completion 2013-12
Phase Phase 2
Johns Hopkins University

1,448 total trials

What the finished NCT00940901 record still lists

NCT00940901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00940901 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00940901 about?

NCT00940901 is a clinical study titled "Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia". This research is being done to evaluate if the phosphodiesterase type 5 (PDE5) inhibitor sildenafil has an effect on the frequency of recurrent priapism and the quality of life of males with sickle cell disease (SCD).

What is the current status of trial NCT00940901?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2008-06. Estimated completion is 2013-12.

What conditions does trial NCT00940901 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Priapism.

What interventions are being tested in trial NCT00940901?

The interventions under investigation include: placebo (OTHER), sildenafil (DRUG).

Who is sponsoring clinical trial NCT00940901?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00940901 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00940901's enrollment target sits among peer trials

13 191st of 213 higher than 22 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00940901, the US trial registry maintained by the National Library of Medicine. NCT00940901 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.